AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Akebia Therapeutics Soars 15.85% on Earnings Surprise
Generated by AI AgentAinvest Movers Radar
Thursday, May 8, 2025 8:27 am ET1min read
Akebia Therapeutics' stock surged 15.85% in pre-market trading on May 8, 2025, driven by strong first-quarter earnings and revenue surprises.
Akebia Therapeutics reported a 200% earnings surprise and a 26.83% revenue surprise for the quarter ended March 2025. The company's performance exceeded analyst expectations, contributing to the significant pre-market rally.
The consensus earnings per share (EPS) estimate for the first quarter of 2025 was -$0.04, while the consensus revenue estimate was $44.53 million, representing a 36.6% year-over-year increase.
has a history of beating EPS estimates, which further bolstered investor confidence.Looking ahead, the company's fiscal year 2025 and 2026 estimate trends show a mix of positive and negative projections, indicating a range of expectations among analysts. However, the strong Q1 performance suggests that Akebia Therapeutics is on track to meet or exceed these estimates.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Dynavax (DVAX) Shares Plunge 1.70% Amid Regulatory and Legal Risks in Sanofi Deal
Dec.24 2025
Intuitive Machines Stock Plunges 12.04% on CEO Share Sale Q3 Loss Acquisition Risks
Dec.24 2025
Repare Therapeutics Dives 2.25% to 12-Month Low Amid Strategic Uncertainty *Key drivers: Pending XenoTherapeutics bid, Gilead asset sale reshape investor sentiment*
Dec.24 2025
Reviva Pharmaceuticals (RVPH) Plunge 55.93% as FDA Demands Additional Trial for Schizophrenia Drug
Dec.24 2025
Fermi Shares Plunge 7.21% to Monthly Low on AICA Termination, Legal Scrutiny
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet